Engineering antigen-presenting cells for immunotherapy of autoimmunity,Advanced Drug Delivery Reviews

当前位置： X-MOL 学术 › Adv. Drug Deliver. Rev. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Engineering antigen-presenting cells for immunotherapy of autoimmunity
Advanced Drug Delivery Reviews ( IF 15.2 ) Pub Date : 2024-05-08 , DOI: 10.1016/j.addr.2024.115329
Clinton T Smith ₁ , Zhenyu Wang ₁ , Jamal S Lewis ₂

Affiliation

Autoimmune diseases are burdensome conditions that affect a significant fraction of the global population. The hallmark of autoimmune disease is a host’s immune system being licensed to attack its tissues based on specific antigens. There are no cures for autoimmune diseases. The current clinical standard for treating autoimmune diseases is the administration of immunosuppressants, which weaken the immune system and reduce auto-inflammatory responses. However, people living with autoimmune diseases are subject to toxicity, fail to mount a sufficient immune response to protect against pathogens, and are more likely to develop infections. Therefore, there is a concerted effort to develop more effective means of targeting immunomodulatory therapies to antigen-presenting cells, which are involved in modulating the immune responses to specific antigens. In this review, we highlight approaches that are currently in development to target antigen-presenting cells and improve therapeutic outcomes in autoimmune diseases.

中文翻译：

用于自身免疫免疫治疗的工程抗原呈递细胞

自身免疫性疾病是影响全球很大一部分人口的负担性疾病。自身免疫性疾病的标志是宿主的免疫系统被许可根据特定抗原攻击其组织。自身免疫性疾病无法治愈。目前治疗自身免疫性疾病的临床标准是使用免疫抑制剂，其削弱免疫系统并减少自身炎症反应。然而，患有自身免疫性疾病的人容易受到毒性的影响，无法产生足够的免疫反应来防御病原体，并且更有可能发生感染。因此，人们共同努力开发更有效的手段，将免疫调节疗法靶向抗原呈递细胞，这些细胞参与调节对特定抗原的免疫反应。在这篇综述中，我们重点介绍了目前正在开发的针对抗原呈递细胞并改善自身免疫性疾病治疗效果的方法。

更新日期：2024-05-08

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南